Abstract
A randomised double-blind placebo-controlled trial of intravenous methylprednisolone versus oral methylprednisolone at equivalent high dose was carried out on 35 patients with an acute relapse of multiple sclerosis (MS). After baseline evaluation each was randomly allocated to oral treatment and intravenous placebo or intravenous treatment and oral placebo, receiving 500 mg of methylprednisolone for five consecutive days and with reassessment at days five and twenty-eight. There was no significant difference in response when disability or functional scores were compared in the two groups. Adverse effects were minor and equally distributed. In this study oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abbruzzese G., Gandolfo C., Loeb C. "Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci. 1983 Jun;4(2):169–172. doi: 10.1007/BF02043900. [DOI] [PubMed] [Google Scholar]
- Barnes M. P., Bateman D. E., Cleland P. G., Dick D. J., Walls T. J., Newman P. K., Saunders M., Tilley P. J. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157–159. doi: 10.1136/jnnp.48.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bindoff L., Lyons P. R., Newman P. K., Saunders M. Methylprednisolone in multiple sclerosis: a comparative dose study. J Neurol Neurosurg Psychiatry. 1988 Aug;51(8):1108–1109. doi: 10.1136/jnnp.51.8.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G. F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986 Feb;36(2):238–243. doi: 10.1212/wnl.36.2.238. [DOI] [PubMed] [Google Scholar]
- Goodin D. S. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology. 1991 Jul;41(7):980–985. doi: 10.1212/wnl.41.7.980. [DOI] [PubMed] [Google Scholar]
- KURTZKE J. F. FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS. Neurology. 1965 Jul;15:654–661. doi: 10.1212/wnl.15.7.654. [DOI] [PubMed] [Google Scholar]
- Milligan N. M., Newcombe R., Compston D. A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. doi: 10.1136/jnnp.50.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ozsoylu S., Ertürk G. Oral megadose methylprednisolone for childhood acute idiopathic thrombocytopenic purpura. Blood. 1991 Apr 15;77(8):1856–1857. [PubMed] [Google Scholar]
- Smith M. D., Ahern M. J., Roberts-Thomson P. J. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis. 1988 Jan;47(1):28–33. doi: 10.1136/ard.47.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. doi: 10.1212/wnl.39.7.969. [DOI] [PubMed] [Google Scholar]